|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02279 YONGHE MEDICAL
Nominal 
2.385 0.000 (0.000%) | 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Turnover | 980,638 | 13.823% | 1,808,333 | 1,804,498 | 1,777,258 | 1,412,791 |
| Cost of Sales | (303,724) | -2.411% | (614,096) | (720,286) | (780,072) | (540,212) |
| Gross Profit | 676,914 | 23.003% | 1,194,237 | 1,084,212 | 997,186 | 872,579 |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (330) | -81.154% | (4,617) | (60,507) | (28,386) | (138) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | 97,779 | 158.613% | 105,449 | (255,291) | (585,219) | (109,466) | |
| Taxation | (22,322) | 124.252% | (31,887) | 28,722 | 38,535 | 23,608 | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 64 | 10.345% | 149 | 226 | 290 | 0 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 75,521 | 170.559% | 73,711 | (226,343) | (546,394) | (85,858) | |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 6,256 | -9.149% | 13,168 | 30,602 | 53,469 | (52,155) |
| Depreciation & Amortisation | 115,424 | -7.773% | 243,676 | 315,210 | 334,840 | 224,672 |
| Directors' Emoluments | -- | -- | 4,895 | 4,889 | 4,456 | 4,085 |
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| EPS (cts) | 15.000 | 150.000% | 15.000 | -45.000 | -108.000 | -16.000 |
| DPS (cts) | 0.000 | -- | 7.600 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | 50.667% | -- | -- | -- |
| Cash flow per share ($) | -- | -- | 0.991 | 0.457 | (0.035) | (0.212) |
| NBV per share ($) | 1.572 | -- | 1.500 | 1.360 | 1.788 | 3.008 |
| Remarks: | Real time quote last updated: 25/08/2026 08:21 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 75,521 |
| %Change | 170.559% |
| EPS / (LPS) | RMB 0.150 |
| NBV Per Share (¥) | RMB 1.572 |